Clinical trials: Hepatitis E Infection
Hepatitis B, Chronic
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.
- Trial name
- NCT00034359
- Testing
- ACH-126,443, Lamivudine
- Where
- 3 sites in Bulgaria, Federal Republic of Yugoslavia
- Volunteers
- 79 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Hepatitis B, Hepatitis B, Chronic
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as…
- Trial name
- NCT05630820
- Testing
- Bepirovirsen
- Where
- 171 sites in United States, Argentina and 25 more
- Volunteers
- 857 people
- Sponsor
- GlaxoSmithKline
Hepatitis E
Exposure to Hepatitis E Virus in Occitania, France
The objective of the proposed work is to determine the seroprevalence of HEV in 2023 in a population of blood donors living in Occitania. Compare the current frequency of anti-HEV IgG and IgM markers with that of 2011.
- Trial name
- EVE (NCT06137313)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Hepatitis B, Chronic
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
This study is to evaluate the antiviral efficacy of add-on adefovir to telbivudine in non-responders to telbivudine monotherapy after 24 and 36 initial weeks.
- Trial name
- NCT00537537
- Testing
- Telbivudine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, HIV Infections
Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients
HBe seroconversion is an important goal for anti-HBV treatment, since it is associated with a non progressive liver infection and a better clinical outcome.
- Trial name
- HB01EMVIPEG (NCT00391638)
- Testing
- TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a)
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Acute Hepatitis A, Acute Hepatitis B
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
The purpose of this study is to assess whether two higher doses (280mg or 420mg three times daily)of silymarin therapy are safe and tolerable, and shorten the illness in patients with acute viral hepatitis compared to placebo.
- Conditions
- Acute Hepatitis A, Acute Hepatitis B, Acute Hepatitis C, Acute Hepatitis E
- Trial name
- NCT00755950
- Testing
- Silymarin, Lactose monohydrate
- Where
- 3 sites in Egypt
- Volunteers
- 70 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis E
Clinical Trial of Recombinant Hepatitis E Vaccine
The primary purpose of this study is to determine whether the preventive hepatitis E are effective in the prevention of hepatitis E occurring at least 30 days after the administration of the third dose of vaccine.
- Trial name
- NCT01014845
- Testing
- hepatitis E vaccine, Hepatitis B vaccine
- Where
- China
- Volunteers
- 112,604 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Hepatitis E Infection in Humans and in Environment
Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms.
The present research aims to collect virological and clinical data on hepatitis E virus (HEV) infections, either in acute or chronic forms of HEV infection in North-Eastern France, with liver- or non liver-related symptoms, plus…
- Trial name
- VHENE (NCT03524014)
- Testing
- Only advice for diagnosis and prevention
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Central Hospital, Nancy, France
Hepatitis E
HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
Hepatitis E is the fifth known human viral hepatitis and is probably the most common cause of acute viral hepatitis in the world.
- Trial name
- NCT03488589
- Testing
- serum samples for HEV RNA PCR
- Volunteers
- 150 people
- Sponsor
- Mahmoud Abdel Rahman
Chronic Hepatitis E
The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors
Hepatitis E virus is a single-stranded positive-sense RNA virus with genome of approximately 7.2kb in length. The HEV genome is capped at the 5' end followed by a small untranslated region of 27 nucleotides and polyadenalated at…
- Trial name
- NCT02419625
- Testing
- questionnaires
- Volunteers
- 200 people
- Sponsor
- Carmel Medical Center
Hepatitis A, Hepatitis E Virus Infection
Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis
Hepatitis is an inflammatory condition of the liver that has emerged as a significant global health concern due to its widespread prevalence. Data on ursodeoxycholic acid in acute viral hepatitis remain limited.
- Trial name
- AVH (NCT07525401)
- Testing
- Ursodeoxycholic Acid, Supportive Care
- Volunteers
- 88 people
- Sponsor
- Combined Military Hospital, Pakistan
Chronic Hepatitis B Virus
The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).
The investigators' research is aimed at developing more effective, finite approaches for managing individual patients with chronic hepatitis B (CHB).
- Trial name
- BeNEG-DO (NCT02845401)
- Testing
- Stop NA therapy
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- California Pacific Medical Center Research Institute
Hepatitis B Virus
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs.
- Trial name
- NCT00805675
- Testing
- Telbivudine, Tenofovir, Telbivudine plus tenofovir
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
- Trial name
- NCT02452528
- Testing
- ARC-520, Entecavir, Tenofovir
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Arrowhead Pharmaceuticals
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Hepatitis E, Hepatitis B
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
This is a open label, randomized phase VI study, to assess the safety and immunogenicity of co-administration of Hepatitis E vaccine with Hepatitis B vaccine.
- Trial name
- NCT02584543
- Testing
- HEV vaccine, HBV vaccine
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Chronic Hepatitis B
Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude
Open-labeled, Prospective, Randomized, Multi-center, Interventional, Phase IV study.
- Trial name
- NCT02523547
- Testing
- Cavir, Baraclude
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hepatitis E
Seroprevalence of Hepatitis E in People With an Organ Transplant
Background: The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant.
- Trial name
- NCT02190253
- Where
- 3 sites in United States
- Volunteers
- 447 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HBV
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
The objective of this protocol is the collection and testing of clinical samples to determine the clinical performance of the Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer.
- Trial name
- NCT04904835
- Testing
- Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
- Where
- 5 sites in France
- Volunteers
- 21,210 people
- Sponsor
- Beckman Coulter, Inc.
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier